Download Free Pricing Of Drugs Codeveloped By Federal Laboratories And Private Companies Book in PDF and EPUB Free Download. You can read online Pricing Of Drugs Codeveloped By Federal Laboratories And Private Companies and write the review.

February issue includes Appendix entitled Directory of United States Government periodicals and subscription publications; September issue includes List of depository libraries; June and December issues include semiannual index
Taxol is arguably the most celebrated, talked-about and controversial natural product in recent years. It is celebrated because of its efficacy as an anti-cancer drug and because its discovery has provided powerful support for policies concerned with biodiversity; talked about because in the late 1980s and early 1990s the American public was bombarded with news reports and special programmes about the molecule and its host, the Pacific yew; and controversial because during the early 1990s the drug and the tree became embroiled in a number of very sensitive political issues with wide implications for the conduct of public policy. The Story of Taxol tells this story.
This book examines the politics of cancer, explains how our government is intrinsically tied to cancer research efforts, and documents how major political actors make cancer policy and are influenced in their decision making by political, social, scientific, and economic variables. Is whether we contract cancer—and whether we survive the disease, if we get it—largely just a result of good versus bad luck, or are these outcomes regarding cancer tied to the policies and actions of our federal government? Cancer-treating drug development and approval is overseen by the U.S. Food and Drug Administration, billions of dollars of federal money are devoted towards cancer research, and exposure of citizens to potentially cancer-causing environments or chemicals is regulated by the Environmental Protection Agency. Additionally, all of these factors can be affected by the political motivations of our most powerful politicians. The Politics of Cancer: Malignant Indifference analyzes the policy environment of cancer in America: the actors, the political institutions, the money, and the disease itself, identifying how haphazard U.S. government policy toward cancer research has been and how the president, Congress, government bureaucracies, and even the cancer industry have failed to meet timelines and make the expected discoveries. Whitman Cobb examines funding for the National Cancer Institute and the roles of the executive, Congress, policy entrepreneurs, and the bureaucracy as well as that of the state of cancer science. She argues that despite the so-called "war on cancer," no strategic, comprehensive government policy has been imposed—leading to an indecisive cancer policy that has significantly impeded cancer research. Written from a political science perspective, the book enables readers to gain insight into the realities of science policy and the ways in which the federal government is both the source of funding for much of cancer research and often deficient in setting comprehensive and consistent anti-cancer policy. Readers will also come to understand how Congress, the president, the bureaucracy, and the cancer industry all share responsibility for the current state of cancer policy confusion and consider whether pharmaceutical companies, for-profit cancer treatment hospitals, and interest groups like the American Cancer Society have a personal incentive to keep the fight alive.
The long twentieth century has witnessed a tremendous upsurge in new drugs, remedies and therapeutic strategies. The cultural environments in which they emerged, the social circumstances from which they sprang, and the social effects that remedies engendered are treated in depth in this collection of essays.
This volume brings together all aspects of TAXOL® research, development, and clinical use. It provides comprehensive knowledge of the compound and a perspective of the complex interrelationships needed for its development and production. Each chapter is written by an authority in the field. Chapters are carefully coordinated to maximize information on key topics while avoiding overlap and duplication. Previously unpublished material is presented along with thorough reviews of each topic.